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Abstract: Taxol, a formulation of paclitaxel (PTX), is one of the most widely used anticancer drugs,
particularly for treating recurring ovarian carcinomas following surgery. Clinically, PTX is used in
combination with other drugs such as lapatinib (LAP) to increase treatment efficacy. Delivering drug
combinations with nanoparticles has the potential to improve chemotherapy outcomes. In this study,
we use Flash NanoPrecipitation, a rapid, scalable process to encapsulate weakly hydrophobic drugs
(logP < 6) PTX and LAP into polymer nanoparticles with a coordination complex of tannic acid and
iron formed during the mixing process. We determine the formulation parameters required to achieve
uniform nanoparticles and evaluate the drug release in vitro. The size of the resulting nanoparticles
was stable at pH 7.4, facilitating sustained drug release via first-order Fickian diffusion. Encapsulating
either PTX or LAP into nanoparticles increases drug potency (as indicated by the decrease in IC-50
concentration); we observe a 1500-fold increase in PTX potency and a six-fold increase in LAP potency.
When PTX and LAP are co-loaded in the same nanoparticle, they have a synergistic effect that is
greater than treating with two single-drug-loaded nanoparticles as the combination index is 0.23
compared to 0.40, respectively.
Keywords: Flash NanoPrecipitation; polymer nanoparticle; codelivery; combination therapy; drug
synergy; ovarian cancer; nanomedicine
1. Introduction
Ovarian cancer remains one of the most difficult cancers to treat due to late-stage diagnosis and
its highly malignant nature [1]. Chemotherapies such as Taxol, a formulation of paclitaxel (PTX),
remains to be one of the most widely used cancer treatments, particularly for recurring ovarian
carcinomas following surgery [1–3]. The mechanism of action for PTX is binding to the β-subunit
of tubulin at two sites, which stabilizes the tubulin polymers preventing cytoskeletal rearrangement
for cellular function [4–6]. Stabilizing tubulin results in cell cycle arrests in the G2/M phase [6].
However, there are many challenges with the use of Taxol. There are severe systemic side effects
associated with PTX treatment such as low blood pressure, risk of infection, the formation of blood
clots, and neurotoxicity [7–9]. Additionally, PTX is poorly water-soluble and has low permeability
which limits drug efficacy due to low drug concentrations reaching the tumor site [10]. Clinically, PTX
is used in combination with other drugs to increase the efficacy of treatment by targeting multiple
pathways [11–13].
Paclitaxel is often used in combination with lapatinib (Tykerb, LAP), a class of tyrosine kinase
inhibitors [14–17]. Several studies observed an increase in drug efficacy in terms of tumor cell death
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and decrease in tumor volume when PTX and LAP were used in combination [15,18]; in some cases,
a synergetic effect was observed [19]. However, combination treatment required premedication
before injection, i.e., complex treatment regimens with multiple methods of administration [20,21].
Formulation of drug combinations in nanoparticles could overcome low solubility and permeability of
the drugs to deliver an effective drug dosage to the tumor site and simplify drug regimens to improve
patient adherence, while decreasing side effects [7,22,23].
Co-encapsulation of PTX and LAP may improve the co-localization of the drugs in the tumor
tissue and increase drug efficacy [7,24–27]. For example, PTX and LAP have been co-formulated in a
core-shell structure using polymer micelles. Lapatinib was conjugated to a PEGylated block copolymer
and formulated into micelles encapsulating PTX in the core. Interestingly, formulation into the polymer
micelles increased the potency of the PTX as indicated by a two-fold decrease in the half-maximal
inhibitory concentration (IC-50) concentration in certain types of breast cancer [25]. Although the
increase in potency via formulation into nanoparticles is exciting, this approach requires multiple
steps and covalent modifications of LAP which results in the formation of a new compound, requiring
further testing for FDA approval, a costly and time-consuming process [28].
Nanoparticle formulations co-encapsulating PTX and LAP without the chemical modification
of LAP have also been considered [7,24–27,29]. Vergara et al. co-encapsulated LAP and PTX in
polyelectrolyte nanoparticles by the sonication-assisted layer-by-layer (SLBL) technique. To formulate
these nanoparticles, PTX-chitosan nanoparticles were first formed, followed by the sequential deposition
of alginic acid and chitosan coatings. Lapatinib was co-deposited with chitosan to achieve nanoparticles
with a PTX core and LAP shell. The core-shell nanoparticles showed a significant decrease in cell
viability in vitro compared to PTX-loaded nanoparticles and free PTX [7]. While the results are
promising, the formulation of the nanoparticles was time intensive as each deposition of each layer
required 20–45 min.
Co-loading both LAP and PTX in the nanoparticle core has been achieved using lipopolymer [24]
or Pluronic F127 polymeric micelles [30]. Formulation using the Pluronic F127 suppressed tumor cell
proliferation and decreased IC-50 by 10-folds relative to the free drug combination treatment of PTX
and LAP [30]. These nanoparticles provide the basis for further improvements of drug combinations;
however, the formulation method is challenging to scale up [31]. Furthermore, the drug effect when
co-delivering drugs in nanoparticle form in terms of synergy is not well established.
In this study, we extend the use of Flash NanoPrecipitation (FNP) to PTX and LAP by leveraging
in situ coordination complexation of tannic acid and iron. Flash NanoPrecipitation enables the rapid,
scalable formulation of drug combinations [32]. However, this method has generally been limited to
highly hydrophobic materials (logP > 6) [33]. Encapsulating PTX and LAP using FNP is challenging
due to their relatively weak hydrophobicity (PTX, logP = 3.2 and LAP, logP = 5.4). We encapsulate drugs
(logP < 6) via in situ coordination complex formation of tannic acid–iron (TA–Fe) and stabilization
with an amphiphilic block copolymer. Our focus is on understanding how incorporating multiple
drugs affects nanoparticle self-assembly. Based on our understanding, we establish the formulation
parameters to form PTX NPs, LAP NPs, and PTX–LAP NPs with comparable sizes (~100 nm in
diameter). We perform initial drug release studies in vitro, focusing on the release of PTX. We evaluate
the potency of the nanoparticles in vitro using an ovarian cancer cell line OVCA-432. The core of our
preliminary in vitro evaluation is based on IC-50 values; the effect of co-encapsulating the drugs in
terms of synergy using the combination index is analyzed.
2. Materials and Methods
2.1. Materials
HPLC grade tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), acetonitrile, and Tween 80 were
purchased from Fisher Scientific (Pittsburg, PA, USA). ACS grade tannic acid (TA) and ACS grade iron
(III) chloride hexahydrate (97%) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Paclitaxel
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(PTX, >98%) and lapatinib (LAP, >98%) were obtained from Cayman Chemical Company (Ann Arbor,
MI, USA); phosphate-buffered saline without calcium and magnesium was purchased from Lonza
(Basel, Switzerland). Polystyrene-b-polyethylene glycol (1600-b-500 g/mol) (PS-b-PEG) was obtained
from Polymer Source (Montreal, Quebec, Canada) and was purified by dissolving in THF (~40 ◦C) and
precipitating into diethyl ether then dried by vacuum for two days as previously described [34].
2.2. Cell Culture
Ovarian cancer cell line OVCA-432 was a kind gift from Dr. Xianjun Fang from Virginia
Commonwealth University. The OVCA-432 cells were cultured in RPMI-1640 media containing 2 mM
L-glutamine (ATCC, Manassas, VA, USA) supplemented with 10% Fortified Bovine Calf Serum (FBS,
HyClone Cosmic Calf Serum, Fisher Scientific, Pittsburg, PA, USA), 100 U/mL penicillin and 100 µg/mL
streptomycin (Gemini Bio-Products, West Sacramento, CA, USA), and cultured at 37 ◦C at 5% CO2.
The cells were passaged once a week.
2.3. Nanoparticle Formulation
Flash NanoPrecipitation (FNP) was used to prepare polymer-based nanoparticles encapsulating
the anti-cancer drugs with a hand-operated confined impinging jet (CIJ) mixer with dilution as
previously described [35,36]. Four nanoparticles were formulated that either encapsulated the TA–Fe
complex (TA–Fe NPs), PTX (PTX NPs), LAP (LAP NPs), or both PTX and LAP (PTX–LAP NPs).
To self-assemble the nanoparticles, PS-b-PEG, TA (4 mg/mL), and one or more of the drugs (PTX
and LAP) were dissolved in a water-miscible organic solvent (e.g., THF or DMSO) by sonication
(~40 ◦C) for 10 min to formulate the organic stream. The organic stream was rapidly mixed with the
Fe3+ (aq., 1 mg/mL) at equal volumes, typically 1 mL, in the CIJ mixer. The effluent from the mixer was
immediately diluted in 1X PBS at pH 7.4 for a final organic solvent/water ratio of 1:9 by volume. The
drug concentration in the organic stream of PTX and LAP was varied from 0.5 mg/mL to 2 mg/mL; the
block copolymer concentration was varied relative to the core material. Specifically, the core material
was considered the TA and Fe3+ for the TA–Fe NPs, and for the drug-loaded nanoparticles it was
determined as TA and the drugs encapsulated. The ratio of the PS-b-PEG to the core material was
varied between 1:1 and 2:1 by mass.
Within 24 h of formulation, the nanoparticles were filtered to remove the organic solvent,
unencapsulated drug(s), and excess TA and Fe3+ with Amicon Ultra-2 Centrifugal filters (Amicon
Ultracentrifuge filter (Ultracel 50K, 50,000 NMWL), Merck Millipore Ltd., Burlington, MA, USA) by
centrifuging at 3700× g rpm for ~15–30 min (5804 R 15 amp version, Eppendorf, Hamburg, Germany).
The nanoparticle pellet was resuspended with 1X PBS to a nominal concentration of ~25 mg/mL of
total solids and stored at ~4 ◦C. The nanoparticles were used within 5 days of the FNP to ensure there
was minimal change in particle size and drug loss.
2.4. Nanoparticle Characterization
The size, polydispersity (PDI), and zeta potential of the nanoparticles were characterized
immediately after FNP and after filtration using dynamic light scattering (Malvern Zetasizer ZS,
Malvern Instruments Ltd., Malvern, United Kingdom). The nanoparticle size and polydispersity
index (PDI), a measure of uniformity, were measured by averaging 4 measurements at a scattering
angle of 173◦. Nanoparticles populations with a PDI of less than 0.400 were considered uniform [37].
The nanoparticle size stability at 4 ◦C was observed by measuring size and PDI for up to 3 weeks after
formulation. The concentration of the nanoparticle dispersion following filtration was determined by
thermogravimetric analysis (TGA) (Pyris 1 TGA, Perkin Elmer, Waltham, MA, USA).
Transmission electron microscopy (TEM) samples were prepared by diluting the filtered
nanoparticle dispersions with DI water 1:20 by volume ratio and pipetting 5 µL three times onto a TEM
grid with Formvar/Carbon support films (200 mesh, Cu, Ted Pella, Inc., Redding, CA, USA) and dried
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under ambient conditions. Dilution was necessary to prevent aggregation during drying. The samples
were imaged with a JEOL JEM-1230 (JEOL USA, Inc., Peabody, MA, USA) at 120 kV.
To determine the drug content of the nanoparticles, acetonitrile (1.8 mL) was added to nanoparticles
(50 µL) filtered with Amicon filter, as previously described, and the sample was vortexed so that the
nanoparticles would disassemble. The sample was centrifuged at 10,000× g rpm for 6 min, and then
the supernatant was collected for reverse-phase high-performance liquid chromatography (RP–HPLC)
(1260 HPLC with Quaternary Pump and UV–Vis Diode Array Detector, Agilent, Santa Clara, CA,
USA) fitted with a Luna® 5 µm C18 100 Å, LC Column 250 × 4.6 mm (Phenomenex, Torrance, CA,
USA). The sample was eluted with degassed acetonitrile and water gradient at a flow rate of 1 mL/min
(0–1 min at 80:20, 1–6 of ramp up to 0:100, 6–8 min at 0:100, and ramp down to 80:20 between 8 and
9 min). PTX was measured at a wavelength of 228 nm with a retention time of ~8 min and LAP was
measured at 332 nm with a retention time of ~9 min. The concentration of each drug was determined
by comparing the peak areas with the standard calibration curve. Encapsulation efficiency (EE%)
and drug loading (DL%) were calculated based on Equations (1) and (2), respectively, and the values
reported are the average and standard deviation of three trials.
Encapsulation e f f iciency (EE%) =
Mass o f drug encapsulated
Initial mass o f drug
× 100% (1)
Drug loading (DL%) =
Mass o f drug encapsulated
Total nanoparticle mass
× 100% (2)
2.5. Nanoparticle Drug Release In Vitro
To measure the drug release, 500 µL of concentrated nanoparticle dispersion was loaded into
a 7000 MWCO dialysis unit (Slide-A-Lyzer® MINI Dialysis Unit, Thermo Scientific, Waltham, MA,
USA) and incubated in 0.5% Tween 80 in PBS at pH 7.4 at 37 ◦C, which was replaced every day of
the experiment. Samples (32 µL) at 0 h, 3 h, 6 h, 24 h, 48 h, day 4, day 6, and day 10 were taken from
the nanoparticle dispersion and the remaining drug concentration was determined by RP–HPLC as
previously described. Three replicates of each drug-loaded nanoparticle dispersion were tested.
2.6. Cytotoxicity
OVA-432 cells were seeded at a density of 15 × 103 cell/well in a 96-well plate containing 100 µL
of complete medium. The cells were incubated at 37 ◦C in 5% CO2 overnight. Then the media was
replaced with 100 µL medium containing free drugs or nanoparticles and treated for 48 h. Stock
solutions of free drug were prepared by dissolving PTX (12 mg/mL) or LAP (5 mg/mL) in DMSO
and sonicating for 5 min. Then, the drugs were diluted with complete media and serial dilutions
were performed to achieve concentrations between 200 and 0.0002 µg/mL. Additional DMSO was
added for a final DMSO concentration of 2% v/v. The nanoparticles were concentrated with Amicon
filters (50 kDa MWCO) as previously described and the nanoparticle pellet was diluted with 1X PBS.
The PTX NPs and LAP NPs were individually concentrated to 1,000 µg/mL of drug. The PTX–LAP
NPs were concentrated to 500 µg/mL relative to PTX. The nanoparticle-loaded medium was prepared
by diluting the stock nanoparticle dispersion with complete media and performing serial dilutions for
final concentrations between 200 and 0.0002 µg/mL. The cells were also treated with complete media
and 2% v/v DMSO media as controls for comparison. There were 6 replicates for each experimental
condition. After 48 h, the cell viability was measured with WST-1 assay (Sigma-Aldrich, St. Louis, MO,
USA) according to manufacturing instructions. Briefly, the drug-loaded medium was removed and
100 µL of RPMI-1640 with Phenol Red (Fisher Scientific, Pittsburg, PA, USA) containing 10% WST-1
solution was added to each well as well as to 6 empty wells. The cells were incubated between 45
and 90 min until there was a visible color change to a golden-yellow or the absorbance of control
wells reached at least 0.700 measured with a microplate reader (VersaMax ELISA microplate reader,
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Molecular Devices, San Jose, CA, USA) at a wavelength of 440 nm with background subtraction of
640 nm. The cell viability was determined by subtracting the background noise (wells containing
only 10% WST-1 in media) from the samples and then dividing the sample absorbance by the average
absorbance of the untreated wells. The relative cell viability was expressed as a percentage of the
untreated cells with a mean ± standard deviation of six replicates.
2.7. Cell Cycle Analysis by Flow Cytometry
The cells were seeded at a density of 20 × 104 cells/mL in a 35 mm petri dish containing 3 mL of
complete media. The cells were incubated at 37 ◦C and 5% CO2 until 90% confluence and the media
was replaced every 2 days. The cells were treated with either free PTX, free LAP, PTX NPs, LAP NPs at
the IC-50 concentration, or left untreated for 48 h at 37 ◦C. After 48 h treatment, the cells were stained
with Propidium Iodide (PI Flow Cytometry Kit, Abcam, Cambridge, MA, USA) for flow cytometry
according to the manufacturer’s instructions. Briefly, the cells were trypsinized and the aspirated
medium and PBS were collected to minimize cell loss. The cells were centrifuged at 700× g for 5 min as
necessary. The cells were washed with 1X PBS and fixed with 66% ethanol by slowly adding ethanol
to PBS during vortexing. The cells were stored in ethanol at 4 ◦C for at least 2 h and up to 4 days.
The cells were centrifuged and washed with PBS to remove the ethanol. The 1× Propidium Iodide and
RNase solution was prepared immediately prior to use by mixing 5% v/v of 20× Propidium Iodide
and 0.05% v/v 200X RNase in 1X PBS. Then the cells were resuspended in 200 µL/500,000 cells of 1X
Propidium Iodide and RNase solution and incubated in the dark at 37 ◦C for 30 min. Prior to flow
cytometry, the cell samples were stored on ice and filtered through a cell strainer (Falcon Test Tube with
Snap Cap, Fisher Scientific, Pittsburg, PA, USA). Flow cytometry was performed on a BD FACSCanto™
II Analyzer (BD Biosciences, San Diego, CA, USA) and 10,000 cells were analyzed at an excitation of
488 nm and emission of 670 nm. The samples were analyzed in triplicate.
3. Results and Discussion
3.1. Nanoparticle Preparation and Characterization
Flash NanoPrecipitation (FNP) is a well-established polymer-directed self-assembly method for
preparing size-tunable nanoparticles encapsulating highly hydrophobic molecules (logP > 6). Since
nanoparticle self-assembly involves adsorption of the hydrophobic block of the block copolymer to a
precipitating core material, this process has generally been limited to highly hydrophobic materials
with a logP of six or greater [32,33]. Since PTX is not sufficiently hydrophobic to form stable particles
via FNP directly [38], we explore an alternative approach in which we encapsulate PTX (logP = 3.2)
and LAP (logP = 5.4) using a pH-labile, tannic acid–iron (TA–Fe) based nanoparticle platform [35].
To prepare TA–Fe based nanoparticles, FNP was performed by mixing drug(s), dissolving TA
and PS-b-PEG in a water-miscible (THF or DMSO) organic solvent with iron (III) chloride dissolved in
water in a confined impinging jet mixer. The effluent from the mixer was quenched in a bath of PBS,
pH 7.4, conditions under which the TA–Fe coordination complex is expected to be insoluble. Upon
rapid mixing, the TA and Fe3+ form an insoluble coordinate complex which co-precipitates with the
drug(s) forming the particle core. Precipitation of the core materials is arrested by adsorption of the
hydrophobic block of the block copolymer and the PEGylated end of the block copolymer sterically
stabilizes the nanoparticle in dispersion (Figure S1). The dispersions appeared red which is consistent
with the tris-complex of TA and iron expected at pH 7.4 [31,39]. Nanoparticles encapsulating the TA–Fe
complex (TA–Fe NPs) are 109 ± 5 nm (Figure S2) with a zeta potential of –21.4 ± 2.1 mV consistent
with other PEGylated nanoparticles [33,40].
Our initial goal was to achieve uniform PTX-loaded nanoparticles on the order of 100 nm to allow
for passive targeting [41]. We examined the effect of organic solvent selection, total solids concentration,
ratio of the block copolymer to core materials, and drug concentration on the ability to make uniform
particles and resulting nanoparticle size.
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Two water-miscible organic solvents were considered, THF and DMSO, as the block copolymer;
TA, LAP, and PTX were sufficiently soluble for the self-assembly of nanoparticles via FNP. However,
when DMSO was used for the organic stream, a visible red-purple precipitate formed immediately
upon mixing in the reservoir. With THF, stable PTX-loaded nanoparticle dispersions were achieved
with a zeta potential of –22.1 ± 2.1 mV and no precipitate was observed. These results suggest
that co-precipitation of PTX and the TA–Fe complex and the rate of PS-b-PEG self-assembly is more
appropriately matched using THF as a solvent than DMSO as a solvent. Thus, THF was used as a
solvent in all further experiments.
To further tune the size of the PTX-loaded particles, we examined the effect of other formulation
parameters. At a total solid concentration of 18 mg/mL in the streams and above, there are two
size populations in the intensity weighted distribution with peak diameters of ~30 nm and ~100 nm.
The population with a hydrodynamic diameter of ~30 nm can be attributed to empty block copolymer
micelles [35,42] produced with the PTX-loaded nanoparticles of ~100 nm (Table 1). The inability to
form uniform particles at high concentrations has been previously observed and could be attributed to
a limited affinity between stabilizer and TA–Fe precipitates at high iron concentrations [35].






(mg/mL) Size 1 (nm) * Size 2 (nm) * PDI *
18 2:1 1 107 ± 2 32 ± 1 0.275 ± 0.009
36 2:1 2 113 ± 6 31 ± 1 0.372 ± 0.012
11 1:1 1 170 ± 33 0 0.142 ± 0.053
13.5 1.5:1 1 128 ± 7 0 0.244 ± 0.034
16 2:1 1 111 ± 10 0 0.255 ± 0.021
19 2:1 2 117 ± 3 20 ± 1 0.268 ± 0.009
16 2:1 1 111 ± 10 0 0.255 ± 0.021
14.5 2:1 0.5 134 ± 42 0 0.232 ± 0.145
* The average ± standard deviation of 3 replicates of Flash NanoPrecipitation (FNP) are reported.
To improve particle uniformity, we next examined the ratio of the block copolymer to core
materials (BCP: core with the core defined as a concentration of TA and PTX in the formulation) at
reduced total solids concentration. Specifically, three BCP: core ratios, i.e., 1:1 1.5:1, and 2:1, were
studied with a total solid concentration of less than 16 mg/mL. All three ratios produced uniform
nanoparticles with a PDI < 0.400. At a 1:1 BCP: core ratio, the particles were 170 ± 33 nm. Increasing
the amount of block copolymer from a 1:1 to 2:1 BCP: core ratio produced a 35% decrease in particle
size (Table 1) and, for the 2:1 BCP: core ratio, uniform PTX-loaded particles with a hydrodynamic
diameter of 117 ± 3 nm were achieved. TEM confirmed the nanoparticles were spherical and the size
was consistent with DLS (Figure S3A). This trend has been attributed to an increase in the rate of
self-assembly relative to the rate of core growth, limiting the growth of the core before it is kinetically
stabilized. These results are comparable to FNP systems using hydrophobic core materials (logP > 6)
in which the particle size can be tuned by varying the ratio of the block copolymer to the core [32,39].
Thus, we next investigated the effect of PTX concentration to maximize the drug loading in the
nanoparticle while maintaining uniform, ~100 nm nanoparticle formulations (Figure 1). We varied
the PTX concentration from 0.5 to 2 mg/mL in the organic stream. Increasing the PTX concentration
to 2 mg/mL resulted in two size populations with peak diameters of ~100 nm and ~20 nm (Table 1)
possibly due to a mismatch time scales of complexation/precipitation and block copolymer micellization
at higher concentrations of the drug. The highest concentration that we used that resulted in uniform
PTX-loaded particles was 1 mg/mL.
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the formation of empty block copolymer micelles. Lowering the total solids concentration to 16 
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Interestingly, the size of the LAP-loaded NPs was independent of BCP: core ratio. This result 
indicates that the concentrations used in the rate of LAP/TA–Fe co-precipitation is comparable to the 
self-assembly of PS-b-PEG micellization. 
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Figure 1. R presentative dynamic light scattering results of uniform (red) paclitaxel nanoparticle (PTX
NPs), (blue) nanoparticle (LAP NPs), and (purple) co-loaded paclitaxel–l patinib n noparticle
(PTX–LAP NPs) samples produced at ~100 nm (each DLS curve is the average of n = 4 measurements).
Rep sentative transmission electron microscopy (TEM) image of PTX–LAP NPs (scale bar = 200 nm)
s inset.
In parallel with formulating PTX-loaded nanoparticles, we also used FNP to encapsulate
LAP within TA–Fe nanoparticles via in situ complexation with the aim of achieving uniform LAP
nanoparticles ~100 nm in diameter.
Similar to PTX, total solids concentration above 36 mg/mL in the streams resulted in two size
populations in the intensity weighted distribution with peak dia eter ~30 n and ~100 n due to the
formation of empty block copolymer micelles. Lowering the total solids concentration to 16 mg/mL,
nanoparticle dispersions with uniform size were achieved (Table 2). Nanoparticle dispersions with
uniform particle size were obtained at BCP to core ratios between 2:1 and 1:1. Interestingly, the size of the
LAP-loaded NPs was independent of BCP: core ratio. This result indicates that the concentrations used
in the rate of LAP/TA–Fe co-precipitation is comparable to the self-assembly of PS-b-PEG micellization.
Table 2. Summary of lapatinib nanoparticle formulations.
Total Solids (mg/mL) Ratio of BCP:Core Size 1 (nm) * Size 2 (nm) * PDI *
16 2:1 91 ± 10 0 0.214 ± 0.038
36 2:1 106 ± 5 26 ± 4 0.288 ± 0.004
10.5 1:1 134 ± 8 0 0.255 ± 0.012
15.3 2:1 126 ± 7 0 0.380 ± 0.037
* The average ± standard deviation of 3 replicates of FNP are reported.
Next, we investigated the effect of LAP concentration to maximize the drug loading in the
nanoparticle while maintaining uniform size distributions (diameter ~100 nm). At LAP concentrations
2 mg/mL nanoparticles were produced at ~150 nm and ~30 nm (Figure S4). These results are
comparable to the results observed with PTX. Reducing the drug concentration, uniform, ~100 nm
particles were achieved and confirmed with TEM imaging (Figure 1 and Figure S3B). These results
suggest co-precipitation of these weakly hydrophobicity drugs (logP < 6) with the TA–Fe core
affects the timescale of precipitation as well as the affinity of the stabilizer and the core that can
result in the formation of empty micelles and need to be considered when formulating these
drug-loaded nanoparticles.
Finally, our goal was to produce co-loaded nanoparticles containing both PTX and LAP (PTX–LAP
NPs). Based on the findings from formulating PTX NPs and LAP NPs, we first focused on drug
concentration using THF as the organic solvent. Using a drug concentration of 1 mg/mL PTX and
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1 mg/mL LAP (a total drug concentration of 2 mg/mL), nanoparticles with multiple two size populations
(peak diameters of 119 ± 28 nm and 22 ± 3 nm) were observed. When the total drug concentration was
decreased to 1 mg/mL (0.5 mg/mL each of PTX and LAP), uniform nanoparticles were produced at
115 ± 3 nm (Table S1). These results are comparable with PTX NPs and LAP NPs where a maximum
drug concentration of 1 mg/mL could be used in the formation of monodispersed nanoparticles.
To maximize the drug loading, a BCP: core ratio of 1:5:1 was used. TEM confirms the particles are
spherical and the particle size is consistent with DLS (Figure 1 and Figure S3C). Additionally, the
nanoparticle size and polydispersity were unaffected by the filtration process (Table S2). Nanoparticle
size was stable for up to two weeks after FNP when stored at 4 ◦C (Table S3).
Following FNP, the drug concentration in the resulting dispersions was determined by HPLC
after disassembling the nanoparticles with acetonitrile. From the drug concentration, the encapsulation
efficiency and drug loading of PTX and LAP were determined. The encapsulation efficiency of
the drug is the amount of drug encapsulated compared to the nominal amount in the formulation.
The drug loading of PTX and LAP in the single-drug-loaded nanoparticles were similar (Table 3)
and comparable to previous literature using polymer micelles [27,43]. For the single-drug-loaded
nanoparticles, the encapsulation efficiency PTX and the LAP were 37.6% ± 14.4% and 25.0% ± 1.5%,
respectively, which are comparable to previous reports using polymer micelles [43]. Interestingly,
in the co-loaded nanoparticles, the encapsulation efficiency of PTX increases from 37.6% ± 14.4% to
67.0% ± 2.2% while the encapsulation efficiency for LAP in PTX–LAP NPs remained the same as
the LAP NPs (Table 3). This result could be attributed to a more hydrophobic core environment in
the presence of LAP facilitating encapsulation of PTX. Due to the selective increase in encapsulation
efficiency of PTX in the presence of LAP, the drug loading of PTX was 2.7-fold higher than the LAP
loading (2.11% ± 0.50% compared to 0.79% ± 0.49%) despite using equal amounts of each drug during
mixing (0.5 mg/mL of each). Notably, these drug concentrations are comparable to previous studies
micelles [27,43].
Table 3. Encapsulation efficiency and drug loading of nanoparticles.
Samples Encapsulation Efficiency (EE%) * Drug Loading (DL%) *
PTX LAP PTX LAP
PTX NPs 37.6 ± 14.4 - 3.11 ± 1.88 -
LAP NPs - 25.0 ± 1.5 - 1.82 ± 0.71
PTX-LAP NPs 67.0 ± 2.2 25.9 ± 3.5 2.11 ± 0.50 0.79 ± 0.40
* The average ± standard deviation of 3 replicates of FNP are reported.
3.2. Drug Release
As a first step to understanding the in vitro drug release rates of PTX and LAP from nanoparticles,
dialysis was performed with PBS at pH 7.4 with Tween 80 similar to previous studies [44–47]. Examining
the PTX-loaded nanoparticles, a burst release was observed within the first six hours at which ~20% of
PTX was released. After six hours, the burst release was followed by sustained PTX release and the
drug release plateaued at ~40% on day six (Figure 2A). In comparison, ~25% of LAP released from
LAP-loaded NPs in the first three hours (~25%). Following the burst release, the sustained release of
LAP release over six days was observed with ~35% total drug release achieved (Figure 2B).
PTX release from the co-loaded nanoparticles was comparable to the single-drug-loaded
nanoparticles with burst release in the first six hours and cumulative drug release at day six of
~40%. We examined the drug release kinetics of PTX from single-drug and co-loaded nanoparticles
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where the Mt is the drug release at time, t, M∞ is maximum drug release, and a is the release rate.
The diffusion exponent, n, is determined based on the fit and described the drug release mechanism [48].
The diffusion exponent for PTX released from PTX NPs and from PTX–LAP NPs was 0.34. Since the
diffusion exponent was less than 0.45, it indicates first-order Fickian diffusion kinetics [50,51].
Examining the LAP release, we observe a slight decrease in cumulative release after 24 h (Figure 2B).
The fluctuations for lapatinib release from the nanoparticles are unusual but similar observations
have been previously reported in other drug release systems [52,53]. The fluctuations in cumulative
release can be potentially attributed to the supersaturation of lapatinib in the dialysis media in the
first 24 h due to the burst release of the drugs from the nanoparticles. Supersaturation could cause
nanoprecipitation of LAP which could result in the apparent drop in cumulative drug accumulation [54].
This phenomenon has been observed with other hydrophobic drugs from nanoparticles [52,54].
Investigating release from the PTX–LAP NPs, there is a decrease in cumulative release in
LAP between 6 and 24 h (Figure 2C). This result suggests that the release of PTX increases the
supersaturation of and nanoprecipitation of LAP. Notably, when comparing LAP release from the
co-loaded nanoparticles to the single-drug-loaded nanoparticles, burst release occurred over six days
rather than three days and the cumulative LAP release at six days was two-folds lower for co-loaded
nanoparticles compared to the single-drug nanoparticle (~16% compared to ~35%) (Figure 2C).
Co-encapsulating PTX and LAP into nanoparticles resulted in a decrease in the cumulative drug
release of LAP but the drug release was comparable for PTX to single-drug-loaded nanoparticles.
The slower burst release of LAP from co-loaded nanoparticles may be attributed to lower drug loading
concentrations compared to LAP NPs resulting in a slower dissolution profile, a phenomenon observed
with hydrophobic materials [55]. These results are consistent with previous literature indicating LAP
has a slower release profile compared to PTX from polymer micelles [30]. Studies to further characterize
the drug release, especially LAP, using alternative media (e.g., other surfactants, or biologically relevant
media such as full growth medium with serum) will be pursued in future work.
Nanomaterials 2020, 10, x FOR PEER REVIEW 9 of 17 
 
where the Mt is the drug release at time, t, M∞ is maximum drug release, and a is the release rate. The 
diffusion exponent, n, is determined based on the fit and described the drug release mechanism [48]. 
The diffusion exponent for PTX released from PTX NPs and from PTX–LAP NPs was 0.34. Since the 
diffusion exponent was less than 0.45, it indicates first-order Fickian diffusion kinetics [50,51].  
Examining the LAP release, we observe a slight decrease in cumulative release after 24 h (Figure 
2B). The fluctuations for lapatinib release from the nanoparticles are unusual but similar observations 
have been previously reported in other drug release systems [52,53]. The fluctuations in cumulative 
release can be potentially attributed to the supersaturation of lapatinib in the dialysis media in the 
first 24 h due to the burst release of the drugs from the nanoparticles. Supersaturation could cause 
nanoprecipitation of LAP which could result in the apparent drop in cumulative drug accumulation 
[54]. This phenomenon has been observed with other hydrophobic drugs from nanoparticles [52,54]  
Investigating release from the PTX–LAP NPs, there is a decrease in cumulative release in LAP 
between 6 and 24 h (Figure 2C). This result suggests that the release of PTX increases the 
supersaturation of and nanoprecipitation of LAP. Notably, when comparing LAP release from the 
co-loaded nanoparticles to the single-drug-loaded nanoparticles, burst release occurred over six days 
rather than three days and the cumulative LAP release at six days was two-folds lower for co-loaded 
nanoparticles compared to the single-drug nanoparticle (~16% compared to ~35%) (Figure 2C). Co-
encapsulating PTX and LAP into nanoparticles resulted in a decrease in the cumulative drug release 
of LAP but the drug release was comparable for PTX to single-drug-loaded nanoparticles. The slower 
burst release of LAP from co-loaded nanoparticles may be attributed to lower drug loading 
concentrations compared to LAP NPs resulting in a slower dissolution profile, a phenomenon 
observed with hydrophobic materials [55]. These results are consistent with previous literature 
indicating LAP has a slower release profile compared to PTX from polymer micelles [30]. Studies to 
further characterize the drug release, especially LAP, using alternative media (e.g., other surfactants, 
or biologically relevant media such as full growth medium with serum) will be pursued in future 
work. 
 
Figure 2. The cumulative drug release of paclitaxel (PTX) and lapatinib (LAP) from polymer 
nanoparticles (NPs) from (A) PTX from PTX NPs, (B) LAP from LAP NPs, and (C) PTX and LAP from 
co-loaded nanoparticles. The graph shows the average ± standard deviation of 3 replicates of FNP 
and independent drug release assays.  
3.3. Assessing Drug Efficacy of Single-Drug Nanoparticles 
Finally, the efficacy of the nanoparticle dispersions was assessed in vitro with ovarian cancer 
cells, OVCA-432. Specifically, we used the IC-50 concentration, i.e., the drug concentration that 
reduces the cell viability by 50%, as a measure of potency. As a control, the cell viability was first 
examined for cells treated with TA–Fe nanoparticles without drugs. When treated with 50 µg/mL 
based on total solids concentration the cell viability was 95% (Table S4). Examining the dose–response 
curve, the IC-50 concentration for the TA–Fe nanoparticles was ~1000 µg/mL of total solids 
concentration. This result demonstrates that the nanoparticle platform itself has minimal cytotoxic 
effects consistent with previous reports [35]. 
Next, we compared the potency of the nanoparticles compared to the free drug at the equivalent 
free drug concentration. We note at the concentrations of nanoparticles used, the (TA–Fe NPs) alone 
Figure 2. The cumulative drug release of paclitaxel (PTX) and lapatinib (LAP) from polymer
nanoparticles (NPs) from (A) PTX from PTX NPs, (B) LAP from LAP NPs, and (C) PTX and LAP from
co-loaded nanoparticles. The graph shows the average standard deviation of 3 replicates of FNP and
independent drug release assays.
3.3. Assessing Drug Efficacy of Single-Drug Nanoparticles
Finally, the efficacy of the nanoparticle dispersions as assessed in vitro with ovarian cancer cells,
OVCA-432. Specifically, we used the IC-50 concentration, i.e., the drug concentration that reduces
the cell viability by 50%, as a measure of potency. As a control, the cell viability was first examined
for cells treated with TA–Fe nanoparticles without drugs. When treated with 50 µg/mL based on
total solids concentration the cell viability was 95% (Table S4). Examining the dose–response curve,
the IC-50 concentration for the TA–Fe nanoparticles was ~1000 µg/mL of total solids concentration.
This result demonstrates that the nanoparticle platform itself has minimal cytotoxic effects consistent
with previous reports [35].
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Next, we compared the potency of the nanoparticles compared to the free drug at the equivalent
free drug concentration. We note at the concentrations of nanoparticles used, the (TA–Fe NPs) alone
did not induce cytotoxic effects and the IC-50 was reproducible with OVCA-432 cells (Table S5).
Encapsulating the PTX shifts the dose–response curve to lower concentrations compared to free PTX
(Table S6) indicating an increase in potency upon encapsulation. A similar trend was observed for
LAP (Figure S5). Interestingly, the dose–response curve of PTX NPs and LAP NPs plateaued at ~20%
cell viability. At low drug concentrations, the TA in the nanoparticle could counter the effects of the
drugs by inducing an antioxidant effect and eliminate free radicals produced with the anticancer
drugs [56,57].
Specifically, the IC-50 concentration decreases from 70.6±5.1µg/mL for free PTX to 0.040±0.003µg/mL
when encapsulated (p < 0.05) (Table 4). A similar result was observed for LAP; upon encapsulation,
there was a nearly six-fold increase in potency as the IC-50 decreased from 4.6 ± 1.3 µg/mL for the free
drug to 0.80 ± 0.26 µg/mL when formulated into nanoparticles (p < 0.05) (Table 4). While decreases in
IC-50 concentration compared to the free drug form have been observed in other polymer nanoparticle
formulations [24,58,59] and are not fully understood, the 1500-fold increase in PTX potency in this
nanoparticle is noteworthy. The significant increase in PTX potency in the TA–Fe could be attributed to
several contributing factors including sustained release over the 48-hour treatment period and increased
bioavailability due to the nanoparticle formulation [24,60,61].
Table 4. IC-50 of paclitaxel, paclitaxel nanoparticles, lapatinib, and lapatinib nanoparticles in
OVCA-432 cells.
Drug Treatment IC-50 (µg/mL) **
PTX LAP
Free PTX * 70.6 ± 5.1 -
Free LAP * - 4.6 ± 1.3
PTX NPs 0.040 ± 0.003 -
LAP NPs - 0.80 ± 0.26
* In 2% DMSO with full growth medium. ** The average ± standard deviation (n = 6 treatments) are reported.
3.4. Cell Cycle Analysis
To better understand the increase in drug potency upon encapsulation, we examined the effect
of treatment on the cell cycle using flow cytometry. The difficulty of treating cancer is the rapid
proliferation of tumor cells and the propensity for metastasis. It is vital that cancer treatments such as
PTX inhibit proliferation. For example, PTX arrests cells in the G2/M phase by stabilizing microtubules
and preventing their disassembly necessary for cell division [62]. Thus, we examined the effect of the
nanoparticles on the cell cycle using flow cytometry. Specifically, we compared the cell cycle of cells
treated with free PTX and PTX NPs at their respective IC-50 concentrations. The untreated control cells
were primarily in the G0/G1 phase with only 9% in the G2/M phase. With free PTX, the percentage
of cells in the G0/G1 phase drops from 62% to 45% and there is an increase in the number of cells in
the G2/M phase to 31% (Figure 3A). These results indicate that free PTX formulations accumulate
OVCA-432 cells in the G2/M phase and likely decrease the cell viability by preventing progression to
mitosis [62]. LAP and LAP-NP-treated cells remained primarily in the G0/G1 phase (Figure 3B) and the
proportions for LAP and LAP NPs were comparable. Thus, free LAP and LAP NPs seem to stabilize
the cells in the G0/G1 phase over the 48-hour treatment with minimal progression to the subG1 phase
as expected since LAP is known to arrest cancer cells in the G1 phase of the cell cycle [63].
Nanomaterials 2020, 10, 561 11 of 17




Figure 3. Cell cycle analysis of OVCA-432 cells from flow cytometry to compare free drug (in 2% v/v 
DMSO) and nanoparticle formulations for (A) paclitaxel (PTX) and (B) lapatinib (LAP). The graph 
shows the average ± standard deviation from 3 replicate wells.  
While the control nanoparticles had no effect on the cell cycle (Figure S6), when OVCA-432 cells 
were treated with PTX NPs the proportion of cells in the G0/G1 phase is similar to free PTX treated 
cells. Notably, treatment with PTX NPs shifted the cells to the subG1 phase relative to both free PTX 
and control (Figure 3A) and decreased the proportion of cells in the G2/M phase from 31% to 11%. 
Increase proportion in the subG1 phase could indicate that cells spend a shorter time in the G2/M 
phase with rapid DNA fragmentation [64] or it could be attributed to a short period of G1 arrest 
followed by progression to the subG1 phase during the 48-hour treatment [65]. Importantly, cells in 
the subG1 phase undergo DNA damage, which can lead to cell death over time [66]. Overall, these 
changes in the cell cycle support our findings that encapsulation increases PTX potency compared to 
free PTX.  
3.5. Drug Combination and Synergy 
Next, we examined the efficacy of the co-loaded formulation. Co-encapsulating the PTX with 
LAP further shifted the dose–response curve to lower concentrations compared to free PTX (Figure 
4). Co-encapsulating PTX and LAP further increases PTX potency as indicated by the two-fold 
decrease in IC-50.  
Figure 3. Cell cycle analysis of OVCA-432 cells from flow cytometry to compare free drug (in 2% v/v
DMSO) and nanoparticle formulations for (A) paclitaxel (PTX) and (B) lapatinib (LAP). The graph
shows the average ± standard deviation from 3 replicate wells.
While the control nanoparticles had no effect on the cell cycle (Figure S6), when OVCA-432 cells
were treat d with PTX NPs the proportion of cells in the G0/G1 phas is similar to free PTX treated
c lls. Notably, treatment with PTX NPs shift d the cells to the subG1 phase relativ to both fre PTX
and control (Figure 3A) and decreased the proportion of cells in the G2/M phase fr m 31% to 11%.
Increase proportion in the subG1 phase could indicate that cells spend a shorter time in the G2/M
phase with apid DNA fragment tion [64] or it could be attribute to a sho t period of G1 arrest
followed by progression to the subG1 phase during th 48-ho r treatment [65]. Importantly, c lls in
the su G1 phas undergo DNA damage, which can lead to cell death over ti e [66]. Overall, these
changes in the cell cycle support our findings that ncapsulation increases PTX potency compared to
fre PTX.
3.5. Drug Combination and Synergy
Next, we examined the efficacy of the co-loaded formulation. Co-encapsulating the PTX with
LAP furth r shifted the dose–response curve to lower concentrations compared to free PTX (Figure 4).
Co-encap ula ing PTX and LAP furthe increases PTX potency as indicated by the two-fold dec ase
in IC-50.
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Figure 4. The cell viability dose–response curve of OVCA-432 cells when treated with (blue) paclitaxel
nanoparticles (PTX NPs) and (red) paclitaxel–lapatinib nanoparticles (PTX–LAP NPs). The PTX–LAP
NPs treatment shifts the dose–response curve to lower drug concentrations compared to the PTX NPs
treatment. The graph shows the average ± standard deviation from one experiment performed with 6
replicate wells.
Based on the IC-50 of PTX–LAP NPs, we compared the cell viability of OVCA-432 cells treated
with a single-drug nanoparticle (0.009 µg/mL PTX or 0.004 µg/mL LAP) to co-loaded PTX–LAP
NPs (Table 5). The control nanoparticles containing no drug (TA–Fe NPs) at the same total solid
concentration (~0.5 µg/mL) exhibited no cytotoxic effects on the OVCA-432 cells. When the OVCA-432
cells were treated with PTX NPs, there was a slight decrease in the cell viability to ~80% whereas LAP
NPs did not significantly affect cell viability. As expected, the PTX–LAP NPs reduced cell viability to
~50% which was significantly lower compared to both PTX NPs (p = 0.0002) and LAP NPs (p = 0.0001)
(Figure 5). These results indicate that at equivalent drug concentrations, co-loaded PTX–LAP NPs had
the greatest potency.
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Building on these results, we compared the combination treatment to the single-drug treatment
to determine if there was a synergistic effect of co-treating the cells with PTX and LAP. Synergy was
examined with the combination index (CI) based on the Chou–Talalay method and when the CI is
below one, the combination treatment is synergistic compared to the sum of the individual drug
treatments [67–69]. Free PTX and free LAP can be combined synergistically as indicated by the CI of
0.18. PTX and LAP target different mechanisms of the cell to produce an anticancer effect [70,71]. LAP
inhibits the function of ABC transporters, which helps increase the intracellular concentration of PTX
thereby increasing drug efficacy [24,72,73]. Similar synergistic effects were seen with chemotherapeutic
agents and tyrosine kinase inhibitors [12,13].
Interestingly, the CI of the co-loaded PTX–LAP NPs was 0.23 comparable to the free drug
combination and lower than co-delivered nanoparticles, which had a CI of 0.40 (Table 5). These results
indicate an advantage to the co-encapsulation of both drugs within the same particle. The co-loaded
nanoparticles could enhance the co-localization of the drugs particularly if the nanoparticles are
endocytosed by tumor cells. Overall, we have presented a rapid and scalable approach to encapsulating
chemotherapeutic combinations in a pH-labile nanoparticle platform that enhances the potency
treatment of ovarian cancer in vitro.
Table 5. IC-50 and combination index of paclitaxel–lapatinib nanoparticles (PTX–LAP NPs) (co-loaded)
compared to simultaneous delivery of paclitaxel nanoparticles (PTX NPs) and lapatinib nanoparticles
(LAP NPs) (two single-drug-loaded NPs) in OVCA-432 cells.
Drug Treatment IC-50 (µg/mL) Combination
Index (CI)PTX LAP
PTX NPs and LAP NPs 0.015 ± 0.003 0.007 ± 0.001 0.40
PTX-LAP NPs 0.0090 ± 0.0009 0.0040 ± 0.0004 0.23
The average ± standard deviation from one experiment performed with 6 replicate wells is reported.
4. Conclusions
In conclusion, we demonstrated the encapsulation of weakly hydrophobic drugs (logP < 6) into
polymer nanoparticles in a rapid, scalable FNP process using in situ complexation of TA–Fe. The size
of the resulting nanoparticles is stable at pH 7.4, facilitating sustained drug release via first-order
Fickian diffusion. Importantly, the nanoparticles that encapsulate PTX and LAP are significantly more
potent than the free drugs as indicated by the significantly decreased IC-50. Co-encapsulating PTX
with LAP further increased potency. Additionally, co-encapsulating PTX and LAP had a synergistic
effect compared to the free drug and greater than co-delivery of the single-drug-loaded nanoparticles
indicating an advantage co-encapsulation of both drugs within the same particle. Building on this
promising study, further studies to understand the cytotoxic effects (e.g., apoptosis), nanoparticle
uptake and localization within cells, protein adsorption to nanoparticles, as well as evaluation in
additional cell lines will be considered in future work. This is an intriguing approach for improving
the potency of existing chemotherapeutics.
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